Business Context and Reporting Period
This Form 8-K is a current report filed by AngioDynamics, Inc. on January 10, 2017. The filing serves to disclose a scheduled presentation by the company's President and CEO, James C. Clemmer, and Executive Vice President and CFO, Michael C. Greiner, at the JP Morgan 35th Annual Healthcare Conference on the same date.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document references presentation slides (Exhibit 99.1) which may contain such information, but the text of the 8-K itself contains no numerical financial metrics.
Material Changes
No material changes to financial results or operations are reported in this document. The filing is procedural, intended to satisfy Regulation FD disclosure requirements regarding the upcoming investor presentation.
Guidance, Outlook, and Risks
The filing includes a comprehensive "Forward-Looking Statements" section. It explicitly states that any future projections regarding financial position, results of operations, or business strategy are not guarantees. Key risks and uncertainties identified include:
- Product development and technological advances by competitors.
- Intellectual property infringement claims.
- Regulatory actions by the FDA and other agencies.
- Healthcare reforms and government regulations.
- Results of clinical trials and ongoing litigation.
- Product recalls and liability claims.
- Foreign currency exchange rate fluctuations.
- Integration of purchased businesses.
The company states it has no obligation to update these forward-looking statements.
Investor Verification Checklist
- Review Exhibit 99.1 (Presentation slides) for specific financial data and strategic updates not included in the 8-K text.
- Verify the company's most recent audited financial statements in the Form 10-K for the year ended May 31, 2016, and subsequent Form 10-Q filings.
- Monitor regulatory filings for updates on pending litigation or FDA actions mentioned in the risk factors.
- Confirm the status of product development pipelines and clinical trial results referenced in the forward-looking statements.